TYVENSE 30 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 30 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 30 milligram - 06ba12

TYVENSE 70 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 70 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 70 milligram - 06ba12

TYVENSE 50 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 50 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 50 milligram - 06ba12

TYVENSE 20 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 20 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 20 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

TYVENSE 40 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 40 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 40 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

TYVENSE 60 Milligram Capsules Hard Ireland - English - HPRA (Health Products Regulatory Authority)

tyvense 60 milligram capsules hard

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 60 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.